About Human 5-Hydroxytryptamine Receptor 7B (HTR7B/5-HT7B) Stable Cell Line

5-Hydroxytryptamine Receptor 7B (HTR7B), also known as the 5-HT7B receptor, is a splice variant of the 5-HT7 serotonin receptor and a Class A G protein-coupled receptor (GPCR). Activated by the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT), HTR7B primarily couples to Gs proteins, stimulating adenylate cyclase activity and increasing intracellular cAMP levels. The receptor is expressed predominantly in the central nervous system, as well as in the gastrointestinal tract and vascular smooth muscle, where it regulates neuronal signaling, circadian rhythm, smooth muscle relaxation, and gastrointestinal motility. Like other HTR7 splice variants, HTR7B exhibits similar ligand-binding properties but differs in its intracellular C-terminal domain, which may influence receptor trafficking and signaling.

HTR7B has attracted considerable interest as a therapeutic target for neurological and psychiatric disorders, including depression, anxiety, migraine, sleep disorders, and cognitive dysfunction. Selective agonists and antagonists continue to be investigated for their potential to modulate serotonergic signaling in both CNS and peripheral diseases.

eEnzyme's Human HTR7B Stable Cell Line provides a reliable platform for investigating HTR7B-mediated signaling and evaluating agonists, antagonists, inverse agonists, and novel receptor modulators using cAMP and other GPCR functional assays. The cell line is well suited for receptor characterization, compound profiling, potency determination, and high-throughput drug screening.

Applications

Biological Significance of HTR7B

HTR7B is an important mediator of serotonin signaling through Gs-mediated cAMP activation. The receptor contributes to regulation of neuronal excitability, neurotransmitter release, circadian rhythm, learning, memory, mood, and smooth muscle relaxation. As one of the human HTR7 splice variants, HTR7B provides a valuable model for studying receptor isoform-specific pharmacology and intracellular signaling. Growing evidence suggests that selective modulation of HTR7 receptors may offer therapeutic benefits for depression, anxiety disorders, migraine, cognitive impairment, and gastrointestinal dysfunction. The HTR7B Stable Cell Line provides a robust tool for studying serotonin receptor biology and accelerating the discovery of next-generation therapeutics targeting HTR7-mediated signaling pathways.